The current findings imply that miR-142-3p operates as an oncogene by targeting RhoBTB3 via the HIF-1 signaling and GGT/GSH pathway and that it could be a potential target for RCC treatment, particularly for KIRC. Here, RHOBTB3 is linked to renal cell carcinoma.